Barclays PLC 6-K, filed Feb 7, 2022
Barclays PLC (BCS)
6-K
2022-02-07
For: 2022-02-07
View Original
Added on
April 11, 2026
About this 6-K
Barclays PLC filed this 6-K on February 7, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
February
01, 2022
Barclays PLC
(Name
of Registrant)
1 Churchill Place
London E14 5HP
England
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual
reports
under
cover of Form 20-F or Form 40-F.
Form
20-F x Form 40-F
Indicate
by check mark whether the registrant by furnishing the
information
contained
in this Form is also thereby furnishing the information to
the
Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
Yes No
x
If
"Yes" is marked, indicate below the file number assigned to the
registrant
in
connection with Rule 12g3-2(b):
This
Report on Form 6-K is filed by Barclays PLC.
This
Report comprises:
Information
given to The London Stock Exchange and furnished pursuant
to
General
Instruction B to the General Instructions to Form 6-K.
EXHIBIT
INDEX
|
Exhibit
No. 1
|
Total
Voting Rights dated 04 January 2022
|
|
Exhibit
No. 2
|
Publication
of Pricing Supplement dated 07 January 2022
|
|
Exhibit
No. 3
|
Publication
of Final Terms dated 11 January 2022
|
|
Exhibit
No. 4
|
Block
listing Interim Review dated 20 January 2022
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
BARCLAYS
PLC
|
|
|
(Registrant)
|
Date:
February 07, 2022
|
|
By: /s/
Garth Wright
--------------------------------
|
|
|
Garth
Wright
|
|
|
Assistant
Secretary
|
|
|
Exhibit
No. 1
4 January 2022
Barclays PLC
Total Voting Rights
In accordance with the Financial Conduct Authority's (FCA)
Disclosure Guidance and Transparency Rule 5.6.1R, Barclays PLC
notifies the market that as of 31 December 2021, Barclays PLC's
issued share capital consists of 16,752,457,128 Ordinary
shares with voting rights.
There are no Ordinary shares held in Treasury.
The above figure (16,752,457,128) may be used by shareholders (and
others with notification obligations) as the denominator for the
calculation by which they will determine if they are required to
notify their interest in, or a change to their interest in,
Barclays PLC under the FCA's Disclosure Guidance and Transparency
Rules.
- Ends
-
For further information, please contact:
|
Investor Relations
|
Media Relations
|
|
Chris Manners
|
Tom Hoskin
|
|
+44 (0)20 7773 2136
|
+44 (0)20 7116 4755
|
|
|
|
Exhibit
No. 2
Publication of Pricing Supplement
The following pricing supplement (the "Pricing
Supplement") is available for
viewing:
Pricing Supplement in relation to Barclays PLC's issue of USD
400,000,000 Zero Coupon Callable Notes due 2052 under the Barclays
PLC £60,000,000,000 Debt Issuance Programme.
Please read the disclaimer below "Disclaimer - Intended
Addressees" before attempting
to access this service, as your right to do so is conditional upon
complying with the requirements set out below.
To view the full document, please paste the following URL into the
address bar of your browser:
http://www.rns-pdf.londonstockexchange.com/rns/8298X_1-2022-1-7.pdf
A copy of the Pricing Supplement has been submitted to the National
Storage Mechanism and will shortly be available for inspection
at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
For further information, please contact:
Barclays Treasury
1 Churchill Place
Canary Wharf
London E14 5HP
DISCLAIMER - INTENDED ADDRESSEES
IMPORTANT: You must read the following
before continuing: The
following applies to the Pricing Supplement available by clicking
on the link above, and you are therefore advised to read this
carefully before reading, accessing or making any other use of the
Pricing Supplement. In accessing the Pricing Supplement, you agree
to be bound by the following terms and conditions, including any
modifications to them, any time you receive any information from us
as a result of such access.
The Pricing Supplement referred to above must be read in
conjunction with the base prospectus dated 11 March 2021 and the
supplemental base prospectuses dated 4 May 2021, 29 July 2021, 22
October 2021 and 2 November 2021, which together constitute a base
prospectus (the "Prospectus").
THE PRICING SUPPLEMENT MAY NOT BE FORWARDED OR DISTRIBUTED OTHER
THAN AS PROVIDED BELOW AND MAY NOT BE REPRODUCED IN ANY MANNER
WHATSOEVER. THE PRICING SUPPLEMENT MAY ONLY BE DISTRIBUTED OUTSIDE
THE UNITED STATES TO PERSONS THAT ARE NOT U.S. PERSONS AS DEFINED
IN, AND IN RELIANCE ON, REGULATION S UNDER THE U.S. SECURITIES ACT
OF 1933, AS AMENDED (THE "SECURITIES
ACT"). ANY FORWARDING,
DISTRIBUTION OR REPRODUCTION OF THE PRICING SUPPLEMENT IN WHOLE OR
IN PART IS PROHIBITED. FAILURE TO COMPLY WITH THIS NOTICE MAY
RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS
OF OTHER JURISDICTIONS.
NOTHING IN THIS ELECTRONIC PUBLICATION CONSTITUTES AN OFFER OF
SECURITIES FOR SALE IN ANY JURISDICTION. ANY NOTES ISSUED OR TO BE
ISSUED PURSUANT TO THE PRICING SUPPLEMENT AND THE PROSPECTUS HAVE
NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT OR
THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR OTHER
JURISDICTION. ANY NOTES ISSUED OR TO BE ISSUED PURSUANT TO THE
PRICING SUPPLEMENT AND THE PROSPECTUS MAY NOT BE OFFERED, SOLD,
PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN AN OFFSHORE TRANSACTION
TO A PERSON THAT IS NOT A U.S. PERSON IN ACCORDANCE WITH RULE 903
OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT.
Please note that the information contained in the Pricing
Supplement and the Prospectus referred to above may be addressed to
and/or targeted at persons who are residents of particular
countries (specified in the Pricing Supplement and/or the
Prospectus) only and is not intended for use and should not be
relied upon by any person outside these countries and/or to whom
the offer contained in the Pricing Supplement and/or the Prospectus
is not addressed. Prior to relying on the
information contained in the Pricing Supplement and/or the
Prospectus you must ascertain from the Pricing Supplement and the
Prospectus whether or not you are part of the intended addressees
of the information contained therein.
Confirmation of your Representation: In order to be eligible to view the Pricing
Supplement or make an investment decision with respect to any Notes
issued or to be issued pursuant to the Pricing Supplement, you must
be a person other than a U.S. person (within the meaning of
Regulation S under the Securities Act). By accessing the Pricing
Supplement, you shall be deemed to have represented that you are
not a U.S. person, and that you consent to delivery of the Pricing
Supplement via electronic publication.
You are reminded that the Pricing Supplement has been made
available to you on the basis that you are a person into whose
possession the Pricing Supplement may be lawfully delivered in
accordance with the laws of the jurisdiction in which you are
located and you may not, nor are you authorised to, deliver the
Pricing Supplement to any other person.
The Pricing Supplement does not constitute, and may not be used in
connection with, an offer or solicitation in any place where offers
or solicitations are not permitted by law. If a jurisdiction
requires that the offering be made by a licensed broker or dealer
and the underwriters or any affiliate of the underwriters is a
licensed broker or dealer in that jurisdiction, the offering shall
be deemed to be made by the underwriters or such affiliate on
behalf of the issuer in such jurisdiction. Under no
circumstances shall the Pricing Supplement constitute an
offer to sell, or the solicitation of an offer to buy, nor shall
there be any sale of any Notes issued or to be issued pursuant
to the Pricing Supplement, in any jurisdiction in which such
offer, solicitation or sale would be unlawful.
The Pricing Supplement has been made available to you in an
electronic form. You are reminded that documents transmitted via
this medium may be altered or changed during the process of
electronic transmission and consequently none of the issuer, its
advisers nor any person who controls any of them nor any director,
officer, employee nor agent of it or affiliate of any such person
accepts any liability or responsibility whatsoever in respect of
any difference between the Pricing Supplement made available to you
in electronic format and the hard copy version available to you on
request from the issuer.
Your right to access this service is conditional upon complying
with the above requirement.
Exhibit
No. 3
Publication of Final Terms
The following final terms (the "Final Terms") are available for viewing:
Final Terms in relation to Barclays PLC's issue of EUR
1,250,000,000 0.877% Fixed Rate Resetting Senior Callable Notes due
January 2028, issued under the Barclays PLC £60,000,000,000
Debt Issuance Programme.
Please read the disclaimer below "Disclaimer - Intended
Addressees" before attempting
to access this service, as your right to do so is conditional upon
complying with the requirements set out below.
To view the full document, please paste the following URL into the
address bar of your browser:
http://www.rns-pdf.londonstockexchange.com/rns/9951X_1-2022-1-10.pdf
A copy of the Final Terms has been submitted to the National
Storage Mechanism and will shortly be available for inspection
at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
For further information, please contact:
Barclays Treasury
1 Churchill Place
Canary Wharf
London E14 5HP
DISCLAIMER - INTENDED ADDRESSEES
IMPORTANT: You must read the following
before continuing: The
following applies to the Final Terms available by clicking on the
link above, and you are therefore advised to read this carefully
before reading, accessing or making any other use of the Final
Terms. In accessing the Final Terms, you agree to be bound by the
following terms and conditions, including any modifications to
them, any time you receive any information from us as a result of
such access.
The Final Terms referred to above must be read in conjunction with
the base prospectus dated 11 March 2021 (as supplemented by the
prospectus supplements dated 4 May 2021, 29 July 2021, 22 October
2021 and 2 November 2021) which together constitute a base
prospectus (the "Prospectus") for the purposes of Regulation (EU) 2017/1129,
as it forms part of domestic law of the United Kingdom by virtue of
the European Union (Withdrawal) Act 2018, as amended (the
"UK
Prospectus Regulation").
THE FINAL TERMS MAY NOT BE FORWARDED OR DISTRIBUTED OTHER THAN AS
PROVIDED BELOW AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER.
THE FINAL TERMS MAY ONLY BE DISTRIBUTED OUTSIDE THE UNITED STATES
TO PERSONS THAT ARE NOT U.S. PERSONS AS DEFINED IN, AND IN RELIANCE
ON, REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED
(THE "SECURITIES
ACT"). ANY FORWARDING,
DISTRIBUTION OR REPRODUCTION OF THE FINAL TERMS IN WHOLE OR IN PART
IS PROHIBITED. FAILURE TO COMPLY WITH THIS NOTICE MAY RESULT IN A
VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER
JURISDICTIONS.
NOTHING IN THIS ELECTRONIC PUBLICATION CONSTITUTES AN OFFER OF
SECURITIES FOR SALE IN ANY JURISDICTION. ANY NOTES ISSUED OR TO BE
ISSUED PURSUANT TO THE FINAL TERMS AND THE PROSPECTUS HAVE NOT
BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT OR THE
SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR OTHER
JURISDICTION. ANY NOTES ISSUED OR TO BE ISSUED PURSUANT TO THE
FINAL TERMS AND THE PROSPECTUS MAY NOT BE OFFERED, SOLD, PLEDGED OR
OTHERWISE TRANSFERRED EXCEPT IN AN OFFSHORE TRANSACTION TO A PERSON
THAT IS NOT A U.S. PERSON IN ACCORDANCE WITH RULE 903 OR RULE 904
OF REGULATION S UNDER THE SECURITIES ACT.
Please note that the information contained in the Final Terms and
the Prospectus referred to above may be addressed to and/or
targeted at persons who are residents of particular countries
(specified in the Final Terms and/or the Prospectus) only and is
not intended for use and should not be relied upon by any person
outside these countries and/or to whom the offer contained in the
Final Terms and/or the Prospectus is not
addressed. Prior to relying on the
information contained in the Final Terms and/or the Prospectus you
must ascertain from the Final Terms and the Prospectus whether or
not you are part of the intended addressees of the information
contained therein.
Confirmation of your Representation: In order to be eligible to view the Final Terms
or make an investment decision with respect to any Notes issued or
to be issued pursuant to the Final Terms, you must be a person
other than a U.S. person (within the meaning of Regulation S under
the Securities Act). By accessing the Final Terms, you shall be
deemed to have represented that you and any customers you represent
are not U.S. persons, and that you consent to delivery of the Final
Terms via electronic publication.
You are reminded that the Final Terms have been made available to
you on the basis that you are a person into whose possession the
Final Terms may be lawfully delivered in accordance with the laws
of the jurisdiction in which you are located and you may not, nor
are you authorised to, deliver the Final Terms to any other
person.
The Final Terms do not constitute, and may not be used in
connection with, an offer or solicitation in any place where offers
or solicitations are not permitted by law. If a jurisdiction
requires that the offering be made by a licensed broker or dealer
and the underwriters or any affiliate of the underwriters is a
licensed broker or dealer in that jurisdiction, the offering shall
be deemed to be made by the underwriters or such affiliate on
behalf of the issuer in such jurisdiction. Under no
circumstances shall the Final Terms constitute an offer
to sell, or the solicitation of an offer to buy, nor shall there be
any sale of any Notes issued or to be issued pursuant to the
Final Terms, in any jurisdiction in which such offer,
solicitation or sale would be unlawful.
The Final Terms have been made available to you in an electronic
form. You are reminded that documents transmitted via this medium
may be altered or changed during the process of electronic
transmission and consequently none of the issuer, its advisers nor
any person who controls any of them nor any director, officer,
employee nor agent of it or affiliate of any such person accepts
any liability or responsibility whatsoever in respect of any
difference between the Final Terms made available to you in
electronic format and the hard copy version available to you on
request from the issuer.
Your right to access this service is conditional upon complying
with the above requirement.
Exhibit No. 4
BLOCK LISTING SIX MONTHLY RETURN
Date: 20 January
2022
|
Name of applicant:
|
BARCLAYS PLC
|
|||
|
Period of return:
|
From 1 July 2021 - 31 December 2021
|
|||
|
Name of scheme:
|
SAYE Share Option Scheme
|
Barclays Group Share Incentive Plan and Barclays Global
Sharepurchase Plan
|
Barclays Group Share Value Plan
|
Barclays Long Term Incentive Plan
|
|
Class of unallotted securities
|
Ordinary shares of 0.25p each
|
Ordinary shares of 0.25p each
|
Ordinary shares of 0.25p each
|
Ordinary shares of 0.25p each
|
|
Balance of unallotted securities under scheme(s) from previous
return:
|
32,982,296
|
20,793,922
|
0
|
20,932,582
|
|
Plus: The amount by which the block scheme(s) has
been increased since the date of the last return (if any increase
has been applied for):
|
30,000,000
|
40,000,000
|
10,000,000
|
0
|
|
Less: Number of securities issued/allotted under scheme(s) during
period (see LR3.5.7G):
|
12,217,521
|
9,354,784
|
0
|
0
|
|
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
50,764,775
|
51,439,138
|
10,000,000
|
20,932,582
|
|
Name of contact:
|
Garth Wright
|
|||
|
Telephone number of contact:
|
020 7116 3170
|
|||